A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease

Journal of Clinical Investigation

Volumn 96, Issue 6, 1995, Pages 3005-3008

  Serrato, Marisa ^a   Marian, A J ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Division of Cardiology   (United States)

Author keywords

atherosclerosis; genetics

Indexed keywords

ARYLESTERASE;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; GENE LOCATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0028809494     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118373     Document Type: Article

References (23)

1. Marenberg, M. E., N. Risch, L. F. Berkman, B. Floderus, and U. de-Faire. 1994. Genetic susceptibility to death from coronary heart disease in a study of twins. N. Engl. J. Med. 330:1041-1046.
2. Chamberlain, J. C., and O. J. Galton. 1990. Genetic susceptibility to atherosclerosis. Br. Med. Bull. 46:917-940.
3. Landers, E. S., and N. J. Schork. 1994. Genetic dissection of complex traits Science (Wash. DC). 265:2037-2048.
4. Cambien, F., O. Poirier, L. Lecerf, A. Evans, J. P. Cambou, D. Arveiler, G. Luc, J. M. Bard, L. Bara, S. Ricard, L. Tiret, P. Amouyel, F. Alhenc-Gelas, and F. Soubrier. 1992. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (Lond.). 359:641-644.
5. Beohar, N., A. Prather, Q-T. Yu, A. E. Raizner, N. S. Kleiman, R. Robert, and A. J. Marian. 1995. Angiotensin converting enzyme genotype DD is a risk factor for coronary artery disease. J. Invest. Med. 43:275-280.
6. Mackness, M. I., S. Arrol, C. A. Abbott, and P. N. Durrington. 1993. Is paraoxonase related to atherosclerosis. Chem.-Biol. Interactions. 87:161-171.
7. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:152-154.
8. McElveen, J., M. I. Mackness, C. M. Colley, T. Peard, S. Warner, and C. H. Walker. 1986. Distribution of paraoxon hydrolysing activity in the serum of patients after myocardial infarction. Clin. Chem. 32:671-673.
9. Furlong, C. E., R. J. Richter, S. J. Seidel, and A. Motulsky. 1988. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am. J. Hum. Genet. 43:230-238.
10. Humbert, R., D. A. Adler, C. K. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:73-76.
11. Furlong, C. E., L. G. Costa, C. Hassett, R. J. Richter, J. A. Sundstrom, D. A. Adler, C. M. Disteche, C. J. Omiecinski, C. Chapline, J. W. Crabb, and R. Humbert. 1993. Human and rabbit paraoxonases: Cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. Interactions. 87:35-48.
12. Adkins, S., K. N. Gan, M. Mody, and B. N. LaDu. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52:598-608.
13. Playfer, J. R., C. L. Eze, M. F. Bullen, and D. A. P. Evans. 1976. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J. Med. Genet. 13:337-342.
14. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1175.
15. Ruiz, J., H. Blanche, M-Cl. Blatter-Carin, Ph. Passa, Ph. Froguel, and R. James. 1995. Paraoxonase polymorphism in non-insulin dependent diabetes: A link between lipid oxidation and coronary heart disease. Atherosclerosis. 115(Suppl.):S13 (Abstr.)
16. Marshall, H. W., L. C. Morrison, L. L. Wu, J. L. Anderson, P. S. Corneli, D. M. Stauffer, A. Allen, L. A. Karagounis, and R. H. Ward. 1994. Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Circulation 89:567-577.
17. Damaraju, S., Q-T. Yu, F. Safavi, and A. J. Marian. 1995. Apolipoprotein ∈4 is not a genetic risk factor for coronary artery disease or restenosis following coronary angioplasty. Am. J. Cordiol. 75:1180-1181.
18. Katsuya, T., G. Koike, T. W. Yee, N. Sharpe, R. Jackson, R. Norton, M. Horiuchi, R. E. Pratt, V. J. Dzau, and S. MacMahon. 1995. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet. 345:1600-1603.
19. Ishigami, T., S. Umemur, T. Iwamoto, K. Tamura, K. Hibi, S. Yamagushi, N. Nyuui, K. Kimura, N. Miyazaki, and M. Ishii. 1995. Molecular variant of angiotensiongen gene is associated with coronary atherosclerosis Circulation 91:951-954.
20. Eriksson, P., B. Kallin, F. M. van Thooft, P. Bavenholm, and A. Hamsten. 1995. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA. 92:1851-1855.
21. Eckerson, H. W., C. M. Wyte, and B. N. La Du. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35:1126-1138.
22. Blatter-Garin, M. Cl. H. Blanche, J. Ruiz, Ph. Passa, Ph. Froguel, and R. James. 1995. The relationship between paraoxonase polymorphism and plasma lipid/lipoproteins in non-insulin dependent diabetes. Atherosclerosis. 115:S23 (Abstr.)
23. Kanemitsu, S., N. Tekekoshi, and E. Murakami. 1994. Effects of LDL apheresis on restenosis after angioplasty. Chem. Phys. Lipids. 67/68:339-343.